Alzheon, Inc
Alzheon, Inc. is a clinical-stage biopharmaceutical company based in Framingham, MA, dedicated to developing innovative treatments for Alzheimer's disease and other neurodegenerative disorders. Founded in 2013 by Dr. Martin Tolar, the company is advancing its investigational oral anti-amyloid therapy, valiltramiprosate, through late-stage clinical trials, focusing initially on high-risk patients with the APOE4 gene variant.
With a strong emphasis on precision medicine, Alzheon utilizes its expertise in inhibiting protein misfolding and aggregation to create disease modifying therapies. The company has successfully completed Phase 2 and Phase 3 trials, receiving substantial funding from the National Institute on Aging to support its research efforts.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.